PUBLISHER: TechNavio | PRODUCT CODE: 2126127
PUBLISHER: TechNavio | PRODUCT CODE: 2126127
Global Atopic Dermatitis Drugs Market 2026-2030
The global atopic dermatitis drugs market is forecasted to grow by USD 8353.2 mn during 2025-2030, accelerating at a CAGR of 11.9% during the forecast period. The report on the global atopic dermatitis drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of chronic dermatitis, breakthroughs in biologic therapies, favorable reimbursement and insurance.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope | |
|---|---|
| Base Year | 2025 |
| End Year | 2030 |
| Series Year | 2026-2030 |
| Growth Momentum | Accelerate |
| YOY 2026 | 10.6% |
| CAGR | 11.9% |
| Incremental Value | $8353.2 mn |
Technavio's global atopic dermatitis drugs market is segmented as below:
By Route Of Administration
- Oral
- Topical
- Injectable
By Drug Class
- Biologics
- PDE4 inhibitors
- Corticosteroids
- Calcineurin inhibitors
By Distribution Channel
- Hospital pharmacy
- Retail pharmacy
- Online pharmacy
Geography
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Asia
- Rest of World (ROW)
- Rest of World (ROW)
This study identifies the rise of oral targeted molecules as one of the prime reasons driving the global atopic dermatitis drugs market growth during the next few years. Also, expansion of pediatric treatment indications and integration of digital health solutions will lead to sizable demand in the market.
The report on the global atopic dermatitis drugs market covers the following areas:
- Global atopic dermatitis drugs market sizing
- Global atopic dermatitis drugs market forecast
- Global atopic dermatitis drugs market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global atopic dermatitis drugs market vendors that include AbbVie Inc., Almirall SA, Arcutis Biotherapeutics Inc., Bausch Health Co Inc., Chugai Pharmaceutical Co. Ltd., Eli Lilly and Co., Galderma Group AG, GlaxoSmithKline Plc, Incyte Corp., Johnson and Johnson, Kyowa Kirin Co. Ltd., LEO Pharma AS, Maruho Co. Ltd., Organon and Co., Otsuka Pharmaceutical Co Ltd., Pfizer Inc., Sanofi SA, SHIONOGI Co. Ltd., Teva Pharmaceutical Ltd., Viatris Inc.. Also, the global atopic dermatitis drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Route of Administration
- Executive Summary - Chart on Market Segmentation by Drug Class
- Executive Summary - Chart on Market Segmentation by Distribution Channel
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- 2.3 Factors of disruption
- 2.4 Impact of drivers and challenges
3 Market Landscape
- 3.1 Market ecosystem
- 3.2 Market characteristics
- 3.3 Value chain analysis
4 Market Sizing
- 4.1 Market definition
- 4.2 Market segment analysis
- Market segments
- 4.3 Market size 2025
- 4.4 Market outlook: Forecast for 2025-2030
5 Historic Market Size
- 5.1 Global Atopic Dermatitis Drugs Market 2020 - 2024
- Historic Market Size - Data Table on Global Atopic Dermatitis Drugs Market 2020 - 2024 ($ million)
- 5.2 Route of Administration segment analysis 2020 - 2024
- Historic Market Size - Route of Administration Segment 2020 - 2024 ($ million)
- 5.3 Drug Class segment analysis 2020 - 2024
- Historic Market Size - Drug Class Segment 2020 - 2024 ($ million)
- 5.4 Distribution Channel segment analysis 2020 - 2024
- Historic Market Size - Distribution Channel Segment 2020 - 2024 ($ million)
- 5.5 Geography segment analysis 2020 - 2024
- Historic Market Size - Geography Segment 2020 - 2024 ($ million)
- 5.6 Country segment analysis 2020 - 2024
- Historic Market Size - Country Segment 2020 - 2024 ($ million)
6 Qualitative Analysis
- 6.1 Impact of AI on Global Atopic Dermatitis Drugs Market
- 6.2 Impact of geopolitical conflicts on Global Atopic Dermatitis Drugs Market
7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2025 and 2030
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2025 and 2030
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2025 and 2030
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2025 and 2030
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2025 and 2030
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2025 and 2030
- 7.7 Market condition
8 Market Segmentation by Route of Administration
- 8.1 Market segments
- 8.2 Comparison by Route of Administration
- 8.3 Oral - Market size and forecast 2025-2030
- 8.4 Topical - Market size and forecast 2025-2030
- 8.5 Injectable - Market size and forecast 2025-2030
- 8.6 Market opportunity by Route of Administration
- Market opportunity by Route of Administration ($ million)
9 Market Segmentation by Drug Class
- 9.1 Market segments
- 9.2 Comparison by Drug Class
- 9.3 Biologics - Market size and forecast 2025-2030
- 9.4 PDE4 inhibitors - Market size and forecast 2025-2030
- 9.5 Corticosteroids - Market size and forecast 2025-2030
- 9.6 Calcineurin inhibitors - Market size and forecast 2025-2030
- 9.7 Market opportunity by Drug Class
- Market opportunity by Drug Class ($ million)
10 Market Segmentation by Distribution Channel
- 10.1 Market segments
- 10.2 Comparison by Distribution Channel
- 10.3 Hospital pharmacy - Market size and forecast 2025-2030
- 10.4 Retail pharmacy - Market size and forecast 2025-2030
- 10.5 Online pharmacy - Market size and forecast 2025-2030
- 10.6 Market opportunity by Distribution Channel
- Market opportunity by Distribution Channel ($ million)
11 Customer Landscape
- 11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
- 12.1 Geographic segmentation
- 12.2 Geographic comparison
- 12.3 North America - Market size and forecast 2025-2030
- 12.3.1 US - Market size and forecast 2025-2030
- 12.3.2 Canada - Market size and forecast 2025-2030
- 12.3.3 Mexico - Market size and forecast 2025-2030
- 12.4 Europe - Market size and forecast 2025-2030
- 12.4.1 Germany - Market size and forecast 2025-2030
- 12.4.2 UK - Market size and forecast 2025-2030
- 12.4.3 France - Market size and forecast 2025-2030
- 12.4.4 Italy - Market size and forecast 2025-2030
- 12.4.5 Spain - Market size and forecast 2025-2030
- 12.4.6 The Netherlands - Market size and forecast 2025-2030
- 12.5 Asia - Market size and forecast 2025-2030
- 12.5.1 China - Market size and forecast 2025-2030
- 12.5.2 India - Market size and forecast 2025-2030
- 12.5.3 Japan - Market size and forecast 2025-2030
- 12.5.4 South Korea - Market size and forecast 2025-2030
- 12.5.5 Indonesia - Market size and forecast 2025-2030
- 12.5.6 Thailand - Market size and forecast 2025-2030
- 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
- 12.6.1 Brazil - Market size and forecast 2025-2030
- 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
- 12.6.3 UAE - Market size and forecast 2025-2030
- 12.6.4 Turkey - Market size and forecast 2025-2030
- 12.6.5 Argentina - Market size and forecast 2025-2030
- 12.6.6 Colombia - Market size and forecast 2025-2030
- 12.6.7 South Africa - Market size and forecast 2025-2030
- 12.6.8 Israel - Market size and forecast 2025-2030
- 12.7 Market opportunity by geography
- Market opportunity by geography ($ million)
- Data Tables on Market opportunity by geography ($ million)
13 Drivers, Challenges, and Opportunity
- 13.1 Market drivers
- Rising prevalence of chronic dermatitis
- Breakthroughs in biologic therapies
- Favorable reimbursement and insurance
- 13.2 Market challenges
- High treatment costs and reimbursement barriers
- Stringent regulatory frameworks and compliance
- Safety concerns and adverse effects
- 13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2025 and 2030
- 13.4 Market opportunities
- Rise of oral targeted molecules
- Expansion of pediatric treatment indications
- Integration of digital health solutions
14 Competitive Landscape
- 14.1 Overview
- 14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 14.3 Landscape disruption
- Overview on factors of disruption
- 14.4 Industry risks
- Impact of key risks on business
15 Competitive Analysis
- 15.1 Companies profiled
- Companies covered
- 15.2 Company ranking index
- Company ranking index
- 15.3 Market positioning of companies
- Matrix on companies position and classification
- 15.4 AbbVie Inc.
- AbbVie Inc. - Overview
- AbbVie Inc. - Business segments
- AbbVie Inc. - Key news
- AbbVie Inc. - Key offerings
- AbbVie Inc. - Segment focus
- SWOT
- 15.5 Almirall SA
- Almirall SA - Overview
- Almirall SA - Business segments
- Almirall SA - Key offerings
- Almirall SA - Segment focus
- SWOT
- 15.6 Bausch Health Co Inc.
- Bausch Health Co Inc. - Overview
- Bausch Health Co Inc. - Business segments
- Bausch Health Co Inc. - Key offerings
- Bausch Health Co Inc. - Segment focus
- SWOT
- 15.7 Chugai Pharmaceutical Co. Ltd.
- Chugai Pharmaceutical Co. Ltd. - Overview
- Chugai Pharmaceutical Co. Ltd. - Product / Service
- Chugai Pharmaceutical Co. Ltd. - Key offerings
- SWOT
- 15.8 Eli Lilly and Co.
- Eli Lilly and Co. - Overview
- Eli Lilly and Co. - Product / Service
- Eli Lilly and Co. - Key news
- Eli Lilly and Co. - Key offerings
- SWOT
- 15.9 Galderma Group AG
- Galderma Group AG - Overview
- Galderma Group AG - Business segments
- Galderma Group AG - Key offerings
- Galderma Group AG - Segment focus
- SWOT
- 15.10 GlaxoSmithKline Plc
- GlaxoSmithKline Plc - Overview
- GlaxoSmithKline Plc - Business segments
- GlaxoSmithKline Plc - Key news
- GlaxoSmithKline Plc - Key offerings
- GlaxoSmithKline Plc - Segment focus
- SWOT
- 15.11 Incyte Corp.
- Incyte Corp. - Overview
- Incyte Corp. - Product / Service
- Incyte Corp. - Key news
- Incyte Corp. - Key offerings
- SWOT
- 15.12 Johnson and Johnson
- Johnson and Johnson - Overview
- Johnson and Johnson - Business segments
- Johnson and Johnson - Key news
- Johnson and Johnson - Key offerings
- Johnson and Johnson - Segment focus
- SWOT
- 15.13 Kyowa Kirin Co. Ltd.
- Kyowa Kirin Co. Ltd. - Overview
- Kyowa Kirin Co. Ltd. - Business segments
- Kyowa Kirin Co. Ltd. - Key offerings
- Kyowa Kirin Co. Ltd. - Segment focus
- SWOT
- 15.14 Pfizer Inc.
- Pfizer Inc. - Overview
- Pfizer Inc. - Business segments
- Pfizer Inc. - Key news
- Pfizer Inc. - Key offerings
- Pfizer Inc. - Segment focus
- SWOT
- 15.15 Sanofi SA
- Sanofi SA - Overview
- Sanofi SA - Business segments
- Sanofi SA - Key news
- Sanofi SA - Key offerings
- Sanofi SA - Segment focus
- SWOT
- 15.16 SHIONOGI Co. Ltd.
- SHIONOGI Co. Ltd. - Overview
- SHIONOGI Co. Ltd. - Product / Service
- SHIONOGI Co. Ltd. - Key offerings
- SWOT
- 15.17 Teva Pharmaceutical Ltd.
- Teva Pharmaceutical Ltd. - Overview
- Teva Pharmaceutical Ltd. - Business segments
- Teva Pharmaceutical Ltd. - Key news
- Teva Pharmaceutical Ltd. - Key offerings
- Teva Pharmaceutical Ltd. - Segment focus
- SWOT
- 15.18 Viatris Inc.
- Viatris Inc. - Overview
- Viatris Inc. - Business segments
- Viatris Inc. - Key news
- Viatris Inc. - Key offerings
- Viatris Inc. - Segment focus
- SWOT
16 Appendix
- 16.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 16.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 16.4 Research methodology
- Research methodology
- 16.5 Data procurement
- Information sources
- 16.6 Data validation
- Data validation
- 16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 16.8 Data synthesis
- Data synthesis
- 16.9 360 degree market analysis
- 360 degree market analysis
- 16.10 List of abbreviations
- List of abbreviations
